Company intelligence / Profile preview

Fitoplancton Marino

El Puerto de Santa Maria, Cádiz, Spainfitoplanctonmarino.com ↗

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

The company has successfully developed TetraSOD®, a marine enzyme for healthy aging and sports performance, which has been launched in the U.S. and Canada by LONZA under the Oceanix™ brand.

Therapeutic areas: Metabolic DisordersOther
Modalities: Microalgae-based products
Industry: Food & Nutrition

Partnerships

LONZA (for marketing TetraSOD® as Oceanix™ in U.S. and Canada)Ángel León ("Chef of the Sea")

Beyond the preview

Go deeper on Fitoplancton Marino.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fitoplancton Marino.

Explore the full profile